Literature DB >> 1698250

Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver.

P I Craig1, I Mehta, M Murray, D McDonald, A Aström, P H van der Meide, G C Farrell.   

Abstract

The aim of this study was to clarify the mechanism by which cytochrome P450 (P450)-mediated catalytic activity is decreased following interferon (IFN) administration. Microsomal steroid hydroxylation was assessed to test the hypothesis that IFN selectively decreases the activities of individual P450 isozymes in male rats. Thus, recombinant rat IFN gamma (r-rat IFN gamma) treatment produced 40% and 17% reductions in androst-4-ene-3,17-dione (androstenedione) 6 beta- and 16 beta-hydroxylation, respectively. Androstenedione 16 alpha- and 7 alpha-hydroxylation were unaltered following r-rat IFN gamma treatment. Similar changes in the androstenedione hydroxylation pathways were observed following administration of naturally derived rat IFN alpha/beta. Microsomal levels of P450IIIA2, the male-specific constitutive steroid 6 beta-hydroxylase, were lower after administration of r-rat IFN gamma (42% of control fractions). Furthermore, hepatic P450IIIA2 mRNA was found to be decreased to a similar extent by r-rat IFN gamma. These findings suggest that IFN selectively decreases the content of this isozyme by a mechanism involving altered mRNA regulation. Sex steroids were unlikely to have mediated the decrease in P450IIIA2 levels since serum estradiol and testosterone levels were unchanged by r-rat IFN gamma. In order to determine whether IFN alters the expression of P450IIIA1, a steroid-inducible member of the P450IIIA gene subfamily which is not expressed in untreated rat liver, adult female rats (which lack P450IIIA2) were coadministered pregnenolone 16 alpha-carbonitrile and r-rat IFN gamma. However, IFN failed to impair the induction of androstenedione 6 beta-hydroxylation produced by pregnenolone 16 alpha-carbonitrile. These findings suggest that although IFN decreases the expression of P450IIIA2, it may not down regulate the expression of other steroid-inducible P450IIIA proteins. In view of the existence of human P450IIIA orthologs which catalyze the metabolism of several important therapeutic agents, the findings of this study may help predict possible drug interactions in patients receiving IFN.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698250

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Authors:  S C Piscitelli; W G Reiss; W D Figg; W P Petros
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

2.  Selective role for tumor necrosis factor-α, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen.

Authors:  Ryan D Kinloch; Choon-Myung Lee; Nico van Rooijen; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2011-05-06       Impact factor: 5.858

3.  Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

Authors:  B C Israel; R A Blouin; W McIntyre; S I Shedlofsky
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  Modulation of hepatic cytochrome P450s by Citrobacter rodentium infection in interleukin-6- and interferon-{gamma}-null mice.

Authors:  Beatrice A Nyagode; Choon-Myung Lee; Edward T Morgan
Journal:  J Pharmacol Exp Ther       Date:  2010-08-18       Impact factor: 4.030

Review 5.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

6.  Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium.

Authors:  Madhusudana R Chaluvadi; Ryan D Kinloch; Beatrice A Nyagode; Terrilyn A Richardson; Malik J Raynor; Melanie Sherman; Leposava Antonovic; Henry W Strobel; Dirck L Dillehay; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2008-10-29       Impact factor: 3.922

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.